– Clinically significant pain reduction and quality of life improvements replicated in broad clinical practice – – Clinically significant pain reduction and quality of life improvements replicated in broad clinical practice –
Read more here:
Real-world Study of SPRINT 60-day Peripheral Nerve Stimulation (PNS) Corroborates Published Clinical Study Results
Akadeum to showcase high-purity, high-yield isolation of Human B cells without the need for a column or magnet Akadeum to showcase high-purity, high-yield isolation of Human B cells without the need for a column or magnet
Originally posted here:
Akadeum Life Sciences Unveils Cell Separation Product Expansion at American Association of Immunologist Annual Meeting
Company announcement no. 6 – 226 May 2022
View original post here:
Completion of the acquisition of Aries Global Logistics, update on current trading, and update on full-year outlook for 2022
MONMOUTH JUNCTION, N. J. , May 06, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that Geno Germano, CEO and President of Elucida Oncology, will present at the Bank of America 2022 Healthcare Conference in Las Vegas, NV on Tuesday, May 10, at 4:40pm PST.
Go here to read the rest:
Elucida Oncology to Present at the Bank of America 2022 Healthcare Conference
New York, NY, and Tel Aviv, ISRAEL, May 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd. reported a Day 14 update. The update is from an ongoing 30-day case study by Dr. Lee Morgentaler of a 3CL protease cleanse with Tollovid, a 3CL protease inhibitor dietary supplement, in a patient who experienced COVID Rebound following intervention with Pfizer’s Paxlovid.
Go here to see the original:
Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient
Novo Nordisk – major shareholder announcement
Read this article:
Novo Nordisk A/S:
See the original post here:
Oxurion Announces Results of the Extraordinary and Annual Shareholders’ Meetings of 3 May 2022 and Invitation to the Extraordinary Shareholders’...
SAN DIEGO, May 06, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences:
Link:
Fate Therapeutics to Present at Upcoming May Investor Conferences
HEIDELBERG, Germany, May 06, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the American Society of Clinical Oncology (ASCO) has informed the Company’s collaborator that it has removed the previously announced oral presentation on AFM13-104, the investigator sponsored trial that evaluates AFM13 pre-complexed with NK cells in patients with relapsed/refractory CD30-positive lymphomas, from the upcoming conference program.
Continue reading here:
Affimed Provides Update on ASCO AFM13-104 Oral Presentation
MALVERN, Pa., May 06, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to eight new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Continued here:
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS
Continue reading here:
Avicanna Announces Closing of Strategic Private Placement
Call scheduled for Monday, May 9, 2022 at 10:30 a.m. ET Call scheduled for Monday, May 9, 2022 at 10:30 a.m. ET
Read the original post:
Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat
-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines against viruses expected over the next 18 months ---- Recent presentations reinforce expertise in vaccine design and delivery and potential of Gritstone’s platform technologies in oncology and infectious diseases --
Read more from the original source:
CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update
A recent market research report entitled Exosome Therapeutics Market Size, Share, Growth, Industry Trends, and Forecast, done by our research team depicts the comprehensive and collaborative analysis of industry during past, present, and forecast periods. The report determines historic growth analysis and current scenario of Exosome Therapeutics Market place and intends to offer actionable insights on global market growth projections. The report sheds light on all the industry verticals like competitive market scenario, regional presence, and development opportunities. The next part covers the market competition landscape based on revenue and growth rate. Further, it explains market types, applications, and price analysis.
Get Sample Report at https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&yog
The global exosome therapeutics market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.9% in the forecast period of 2022 to 2029 and is expected to reach USD 1,602.54 thousand by 2029 from USD 468.98 thousand in 2021. The rising prevalence of chronic inflammatory autoimmune diseases and technological developments in exosome therapeutics are likely to be the major drivers which propel the demand of the market in the forecast period.
Some of the major companies providing the global exosome therapeutics market are Stem Cells Group, Exosome Sciences, AEGLE Therapeutics, Capricor Therapeutics, Avalon Globocare Corp, CODIAK, Kimera Labs, Stem Cell Medicine Ltd, Exopharm, Jazz Pharmaceuticals, Inc., evox THERAPEUTICS, ReNeuron Group plc, and EV Therapeutics, among others.
Our Reports Will Help Clients Solve the Following Issues:
Uncertainty about the future: Our research and insights assist our clients forecast revenue compartments and growth ranges in the future. This will assist our clients in investing in or selling their assets.
Grasp market opinions: For a strategy, it is critical to have an objective understanding of market opinions. Our research provides a clear picture of market mood. We maintain this surveillance by engaging with Key Opinion Leaders from each industrys value chain.
Recognizing the most dependable investment hubs: Our analysis assesses market investment centres based on projected demand, returns, and profit margins. By using our market research, our clients may concentrate on the most important investment centres.
Identifying and assessing possible business partners: Our research and insights assist our clients in identifying business partners.
For More Inquiry Contact us at https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&yog
Global Exosome Therapeutics Market, By Type (Natural Exosome, Hybrid Exosome), Source (Mesenchymal Stem Cells, Blood, Body Fluids, Urine, Dendritic Cells, Saliva, Milk, and Others), Therapy (Immunotherapy, Chemotherapy, and Gene Therapy), Transporting Capacity (Bio Macromolecules and Small Molecules), Application (Metabolic Disorders, Oncology, Cardiac Disorders, Neurology, Inflammatory Disorders, Organ Transplantation, Gynecology Disorders, Blood Disorders, and Others), Route of administration (Parenteral and Oral), End User (Research and Academic Institutes, Hospitals and Diagnostic Centers), Country (U.S., Mexico, South Korea, Australia, Hong-Kong, Rest of Asia-Pacific, Brazil, Argentina, Venezuela, Colombia, Ecuador, Peru, Uruguay, Costa Rica, Panama, Dominican Republic, Rest of Latin America and Turkey) Industry Trends and Forecast To 2029
Major Points Covered in Table of Contents:
Click to View Full Report TOC, figure and tables at https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&yog
Some of the important question for stakeholders and business professional for expanding their position in the Exosome Therapeutics Market:
Q 1. Ahead of 2022, which region offers the most lucrative open doors for the market?
Q 2. What are the business threats, as well as the impact of the most recent scenario on market growth and estimation?
Q 3. In terms of applications, types, and areas, what are the most promising, high-development possibilities for the Canned Wine movement?
Q 4.What segments of the Exosome Therapeutics Market are attracting the most attention in 2022 and beyond?
Q 5. Who are the major participants in the Exosome Therapeutics Market, both now and in the future?
Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, LATAM, Europe or Southeast Asia or Just Eastern Asia
Related Trending Market Reports:
Global Auto Parts and Accessories Market, By Product (Engine Parts, Electrical Parts, Drive and Transmission Steering Parts, Suspension and Braking Parts Equipment and Others), Vehicle Type (Passenger, Commercial, Light Commercial Vehicle, Sports Vehicles and Others), Type (Driveline and Powertrain, Interiors and Exteriors, Electronics, Seating, Lighting, and Other Types), Application (OEM, and Aftermarket), Country (U.S., Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of the Middle East and Africa) Industry Trends and Forecast to 2029.
https://www.databridgemarketresearch.com/reports/global-auto-parts-and-accessories-market
Global Database Encryption Market, By Database Encryption Type (Transparent Encryption, Column-Level Encryption, File-System Encryption, Application- Level Encryption, Key Management), Database Operational Models (Data-At-Rest, Data-In-Motion) Deployment Type (On-Premises, Cloud) End User (Smbs, Enterprises) Vertical (IT & Telecom, Banking, Financial Services, And Insurance (BFSI), Healthcare, Retail And E-Commerce, Government & Public Sectors, Aerospace & Defense, Others) Country (U.S., Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, France, Italy, U.K., Belgium, Spain, Russia, Turkey, Netherlands, Switzerland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, U.A.E, Saudi Arabia, Egypt, South Africa, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
https://www.databridgemarketresearch.com/reports/global-database-encryption-market
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Selection of lead candidate from initial short-list of 6 DMT-analogues
Lead candidate displays superior potency in two in vitro bioassays on two relevant human cell types
In vitro safety and biocompatibility testing using drug-loaded medical device demonstrates tolerability at doses anticipated to be within therapeutic range
Results to be leveraged by filing of Provisional Patent detailing a novel approach to treating primary open angle glaucoma
Initiates plans for second stage of R&D with Terasaki Institute for Biomedical Innovation
Toronto, Ontario--(Newsfile Corp. - May 3, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that in collaboration with the Terasaki Institute for Biomedical Innovation (TIBI), has selected its final lead drug candidate from a short list of six N,N-Dimethyltryptamine (DMT) analogue molecules. This decision, based on successful completion of the first phase of the sponsored research agreement, derives from the demonstration of lead candidate superiority as it relates to in vitro potency in two predictive bioassays, a favorable toxicity profile as well as physical, chemical, and metabolic properties necessary to fabricate a proprietary medical device capable of conveniently delivering sub-psychedelic levels of drug to the front of the eye over a sustained period.
With efforts related to discovery and candidate selection now complete, the Company intends to advance its program in primary open angle glaucoma (POAG) by entering into a second sponsored research collaboration with TIBI to undertake 1) mechanism of action studies, 2) optimize medical device drug release characteristics, 3) in vitro host-species justification studies to support, 4) evaluation of drug efficacy in an IND-enabling study of POAG with the goal of providing all necessary support to file an investigative new drug (IND) application with the United States Food and Drug Administration (the "FDA") to conduct clinical studies.
Paul Van Slyke, CSO of PharmaDrug, commented, "We are excited to announce that in collaboration with TIBI, we have successfully completed the studies necessary to elect the Company's lead drug candidate for the treatment of POAG. The next phase of this ongoing collaboration will start shortly and is underlined by the Company's strong commitment to work with outstanding research and development groups from around the world to provide innovative, life changing medications to patients at risk of vision loss as a consequence of insufficiently treated glaucoma."
Story continues
Under the terms of the first sponsored research agreement, PharmaDrug's DMT-analogue research program aimed to elect a drug development lead based on biological potency and toxicity and to use the development lead to engineer a medical device capable of sustained drug delivery to the front of the eye. The Company has now selected its lead candidate and completed fabrication and initial testing of its novel medical device designed to deliver therapeutic quantities of its DMT-analogues to the front of the eye. Specifically, drug-loaded medical device prototypes were suspended in a biological solution meant to mimic the somewhat harsh environment of the eye. Samples, maintained at body temperature were removed at defined periods of time over sixteen days and were quantified to determine concentration and rate of drug release and breakdown. Stability of the lead candidate molecule met necessary criteria set forth by the Company. The biocompatibility of drug-loaded medical device was examined by way of quantifying cell proliferation and live/dead staining on human ciliary muscle cells over time. Concentrations expected to be within the therapeutic range were found to not statistically impact cell viability the drug-loaded medical devices.
Most recently, potency of the lead candidate was evaluated in an in vitro cyclic adenosine 3':5' monophosphate (cAMP) production assay using human, primary trabecular meshwork (TM) cells and ciliary muscle (CM) cells. These cells, richly decorated with serotonin receptor 1a and 2a (5HT-1a, 5HT-2a), play a central role in the maintenance of healthy intraocular pressure. Tryptamine molecules, such as the Company's lead candidate are thought to bind to these receptors and elicit downstream biological outcomes which assist in the active drainage (reduction of pressure) of aqueous humor from the front of the eye to the posterior compartment. The Company's lead candidate demonstrated potent cAMP production following application, a statistically significant superiority compared to other candidate molecules examined (p<0001), and an unexpected bias towards cAMP production in TM cells versus CM cells.
Test article potency was previously evaluated using an in vitro calcium mobilization assay on TM and CM cells. Calcium mobilization is understood to provoke smooth muscle contraction, and specifically in the case of TM and CM cells, is thought to contribute to the maintenance of healthy IOP by channeling aqueous humor away from the front of the eye. The Company's lead candidate was found to activate calcium mobilization, to levels that were comparable or greater than the experimental positive control, ionomycin. The lead candidate was also examined for in vitro toxicity and found to be non-toxic to TM and CM cells at concentrations expected to be used in treatment for various eye diseases. Collectively results from the first phase of the sponsored research agreement will be used to draft an upcoming Provisional Patent application which describes use of tryptamine family members, fabricated into a proprietary medical device, to treat conditions marked by elevated intraocular pressure.
The Need for Improved Medications to Treat Primary Open Angle Glaucoma
Glaucoma is a disorder of the optic nerve that results in irreversible vision loss and is the second leading cause of blindness in the world, according to the World Health Organization. Glaucoma impacts more than 2.7 million people aged 40 or older in the United States and current treatments are known to have poor rates of compliance of up to 80% of patients. The global market for glaucoma was estimated by Market Scope at $4.8 billion in 2019 with the U.S. market representing $1.9 billion. Although the exact etiology of primary open angle glaucoma remains poorly understood, and may be variable across patient subsets, it is generally accepted that the observed increase in IOP correlates with progressive vision loss1. Current treatments for POAG primarily consist of eyedrops that can be grouped into three main categories: prostaglandin analogues, carbonic anhydrous inhibitors, and alpha-2 agonists. While these approaches usually provide partial improvement, they often result in side effects such as redness and stinging and require multiple daily applications; all of which diminish patient compliance. Tryptamines, including DMT-analogues are thought to work in a completely distinct way to lower IOP and as such potentially embody a new class of glaucoma medications that may be used alone, or in combination with already approved medications. The Company's streamlined focus on two highly promising, undisclosed tryptamines as a potential therapeutic solution in treating glaucoma represents a potential paradigm shift.
Modulating the serotonin receptor pathway to improve glaucoma outcomes
Key regions of the eye that regulate fluid dynamics, including maintenance of healthy IOP, are known to be richly decorated with various serotonin receptor family members. Previous research has highlighted the role of serotonin receptor signaling in the regulation of IOP2-5. Tryptamines, often hallucinogenic above certain threshold concentrations, constitute a large collection of molecules that selectively act on multiple different serotonin receptors including 5-HT1A and 5-HT2A. Topical application of several different tryptamines have shown early promise in preclinical models of elevated IOP, however formulation, delivery, the potential for undesirable hallucinogenic side effects, and the controlled substances act of 1970 have all contributed to a lack of development of tryptamines to treat this serious threat to vision.
About Terasaki Institute for Biomedical Innovation
The Terasaki Institute for Biomedical Innovation is a biotechnology institute which develops medical devices and cutting-edge protocols for a variety of diagnostic, monitoring and treatment applications. Their research platforms include work in biomaterials, cellular and tissue engineering, wearable biosensors and organs-on-a-chip, with specific expertise in novel polymer development.
About PharmaDrug Inc.
PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs. PharmaDrug owns 100% of Pharmadrug Production GmbH ("Pharmadrug Production"), a German medical cannabis distributor, with a Schedule I European Union narcotics license and German EuGMP certification allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the European Union. PharmaDrug owns 100% Sairiyo Therapeutics ("Sairiyo"), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the US and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious disease and rare cancers. Sairiyo is also conducting R&D in the psychedelics space for the treatment of non-neuropsychiatric conditions. The Company also owns 100% of Super Smart, a company building a vertically integrated retail business with the goal to elevate the use of functional mushrooms, and psilocybin mushrooms where federally legal, as natural based medicines.
For further information, please contact:
Daniel Cohen, Chairman and CEO dcohen@pharmadrug.co(647) 202-1824
Caution Regarding Forward-Looking Information:
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
This press release contains "forward-looking information" within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. Generally, forward-looking information may be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "proposed", "is expected", "budgets", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. In particular, this press release contains forward-looking information in relation to: future in vivo efficacy testing in an accepted model of primary open angle glaucoma (POAG), the ability to complete the required studies and obtain regulatory approval, and the impact the Company's potential products will have on treating glaucoma. This forward-looking information reflects the Company's current beliefs and is based on information currently available to the Company and on assumptions the Company believes are reasonable. These assumptions include, but are not limited to the ability of the Company to successfully execute on its plans for the Company and its affiliated entities; the ability to obtain required regulatory approvals and the Company's continued response and ability to navigate the COVID-19 pandemic being consistent with, or better than, its ability and response to date.
Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; the actual results of the Company's future operations; competition; changes in legislation affecting the Company; the ability to obtain and maintain required permits and approvals, the timing and availability of external financing on acceptable terms; lack of qualified, skilled labour or loss of key individuals; risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions; and a deterioration of financial markets that could limit the Company's ability to obtain external financing.
A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR website at http://www.sedar.com. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.
Forward-looking information contained in this press release is expressly qualified by this cautionary statement. The forward-looking information contained in this press release represents the expectations of the Company as of the date of this press release and, accordingly, are subject to change after such date. However, the Company expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
References:
Weinreb RN, Leung CK, Crowston JG, Medeiros FA, Friedman DS, Wiggs JL, Martin KR. Primary open-angle glaucoma. Nat Rev Dis Primers. 2016 Sep 22;2:16067. doi: 10.1038/nrdp.2016.67. PMID: 27654570.
May JA, McLaughlin MA, Sharif NA, Hellberg MR, Dean TR. Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. J Pharmacol Exp Ther. 2003 Jul;306(1):301-9. doi: 10.1124/jpet.103.049528. Epub 2003 Apr 3. PMID: 12676887.
Sharif NA. Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action. Curr Drug Targets. 2010 Aug;11(8):978-93. doi: 10.2174/138945010791591278. PMID: 20426763.
Najam A Sharif & Jesse A May (2011) Potential for serotonergic agents to treat elevated intraocular pressure and glaucoma: focus on 5-HT2 receptor agonists, Expert Review of Ophthalmology, 6:1, 105-120, DOI: 10.1586/eop.10.69
Sharif NA, McLaughlin MA, Kelly CR. AL-34662: a potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist. J Ocul Pharmacol Ther. 2007 Feb;23(1):1-13. doi: 10.1089/jop.2006.0093. PMID: 17341144.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/122498
See the original post:
Pharmadrug Advances Opthalmology Program with Final Selection of Lead DMT-Analogue to Provide Sustained Control of Elevated Intraocular Pressure for...
There has been a significant increase in eye diseases in the people of India for the last several years. The doctors of The Retina Centre, Guwahati told the media on this subject that there can be many reasons for eye problems, including pollution, excessive use of mobile Use, stress, use of tobacco and other intoxicants, disordered eating, eye injury etc. are prominent.
Our eyes are precious but our slightest carelessness towards the eyes can also make us a victim of blindness. Many people ignore the initial symptoms of eye problems and gradually these problems take a serious form in them. That is why it is necessary not to ignore eye diseases and consult a doctor immediately as soon as the initial symptoms appear.
The officials of The Retina Center told the media that this institute of theirs has become the best eye hospital in the entire North-East region. Officials said that not only are the best doctors working here, but advanced medical procedures are available at affordable rates through modern resources.
The following eye diseases are treated by The Retina Centre.
Retinal Diseases:
The retina is the tissue that lines the inside of the eye and is sensitive to light. It sends visual messages to the brain through the optic nerve. Retinal diseases can affect any part of the retina and vary widely, but most of them cause visual symptoms. In the hospital, scleral buckling, vitrectomy (without suture), pneumorretinopexy, anti VEGF treatment, laser treatment etc. are done.
Corneal Disorders:
The cornea is a clear layer in front of the iris and the pupil. It protects the iris and lens and helps to focus light on the retina. Corneal disease is a serious condition that can lead to deformity, scarring and eventually blindness. Keratoplasty andTreatment services like Keratoprosthesis are available.
cataracts :
Cataract is a serious disease of the eyes. Cataracts usually occur with ageing or develop for no apparent reason. Most cataracts can be removed and replaced with artificial lenses. For this, facilities like Phacoemulsification with IOL implantation are available in the hospital.
Glaucoma:
Glaucoma is progressive optic nerve damage that leads to irreversible loss of vision. Glaucoma can occur at any age but it is 6 times more common in people over the age of 60. The Retina Center provides treatment for this like Filtration Surgery, Valve Implantation.
eye surgery:
Eye surgery Early diagnosis of eye conditions can help prevent further deterioration in eye health, improve vision and cure most eye diseases. Treatment includes simple medication, non-invasive and invasive procedures may be involved. For this, facilities like Retina Surgery, Glaucoma, Cataract Surgery, Neuro Opthalmology, Squint, Oculoplasty, Pediatric, Opthalmology are available in the hospital.
Hospital Address and Contact:
5th and 6th Floor, Subham Bijay Crescent,
6th Mile, Rukmini Gaon,
GS Road, Guwahati-781022, Assam
http://www.theretinacentre.com
Go here to read the rest:
Best Eye Hospital in North-East Region : The Retina Centre, Guwahati - APN News
Led by Ukrainian doctor practicing in the UK, Dr Sergey Tadtayev a consultant urologist surgeon, staff at Chiltern in Great Missenden, and Shelburne Hospital have managed to deliver supplies to the war-torn country.
Circle Health Group, Sergeys hospital operator, has also played a key role in getting the urgent supplies to Ukraine.
In response to direct requests from Ukrainian doctors, the hospitals have worked with the Ukrainian doctors union (Ukraine Medical Association) and the British Red Cross to identify needs in war-hit hospitals.
Also, Sergey has galvanised his Circle colleagues to gather 10-truck loads including 200 pallets of vital kit and medical supplies from across the groups national network of 53 hospitals.
Sergey said: My heart breaks for my fellow doctors back home who are fighting heroically to care for the sick and wounded even as the bombs continue to fall.
"Hospitals are struggling to get basic supplies because transport and manufacturing have been so badly disrupted, so I knew I had to do something to help.
Moving 100+ tonnes of medical supplies between hospitals separated by thousands of miles and several borders has been an incredible team effort, and I have been overwhelmed by the generosity of my colleagues at Circle Health Group.
"They are moving heaven and earth to get help to those who really need it on the frontline, and I am humbled by the solidarity and support for my homeland.
Ventilators, crutches, walking frames, respiratory masks, scrubs, bandages, wound kits, operating tables and other medical supplies have been stock-piled from Circle hospitals across the country and delivered directly to the doors of five hospitals covering North, South, East and West Ukraine.
Upon receipt of the urgent supplies, the hospitals distribute a portion to local community hospitals.
A team of volunteers from the UK, Poland and Ukraine have made the journey on a weekly basis since 15 March to deliver urgent supplies, navigating their way through war-torn regions and areas of conflict to reach the hospitals in Kyiv, Kharkiv, Mykolaiv, Odessa and Lviv.
Circle Health Group has committed to continue the weekly delivery programme for as long as the supplies are required.
The latest delivery, which departed the UK on Wednesday 13 April and arrived at a Kharkiv hospitals on Easter Sunday (17 April), contained 185,500 of medical equipment loaded on 35 pallets, including five ventilators, an operating table, patient monitors, suction tubing and chest drainage sets and sterile gowns.
One of the hospitals opthalmic consultants, Mandeep Bindra, and Healthcare Assistant Adinda Ecott, co-ordinated the collection of supplies ranging from blankets to hot water bottles and baby food. Mandeep personally drove the supplies to two collection centres, one in Hounslow and one at the Olympic Lodge in Aylesbury.
The collected items will then be transported by lorry to the Polish border where they will be given to Ukrainian families.
Overall, 1.4 million worth of supplies have been sent from Circle Health Group hospitals.
Paolo Pieri, CEO of Circle Health Group, said: Were so grateful to the hundreds of people across the country who have contributed to this effort, from staff to partners and suppliers, and the brave drivers who have put themselves at considerable personal risk."
Read the rest here:
Bucks hospitals rally to deliver urgent supplies to Ukraine - Bucks Herald
Sven Kili, ISCT 2022 Annual Meeting co-chair/Courtesy of YouTube
The cell and gene therapy space is growing up and spawning myriad scientific gatherings, including two on the immediate horizon. On May 16, the 25th annual meeting of the American Society of Gene & Cell Therapy (ASGCT) will commence in Washington, DC. And this week in San Francisco, industry, investors, regulators, physicians and patients will convene at the International Society for Cell & Gene Therapy (ISCT)s annual conference the first to be held in person since 2019.
Sven Kili, CEO at Antion Biosciences and 2022 Annual Meeting co-chair told BioSpace that the conference will set the pace for the next 12 months in terms of the most intriguing technology, key investments and key moves.
We often talk jokingly, but it's actually quite serious, that this represents almost the G7 summit of cell and gene therapy, Kili said. Rather than being a place where partnerships and M&A activity is announced (though that may come after), ISCT is focused on really changing the landscape of the cell and gene therapy space.
A summit evokes the idea of key community leaders coming together to make important decisions, and the organizers of ISCT felt it important that every voice is at the table for every key discussion, as opposed to branching off into their own siloed manufacturing or cancer tracks.
At typical scientific meetings, You have a regulatory track and you have a manufacturing track and everyone toddles off to their own track where they sit in isolation and hear about the latest developments, Kili said. ISCT wanted to provide better educational value for its attendees. So, this years meeting will reflect the development pathway of a cell and gene therapy product.
When you develop a therapy, you sit down with a bunch of different people. You sit down with scientists, you sit down with clinicians, you sit down with patients; you might even have a commercial person and a regulatory person. You have a variety of people around the table," Kili said.
This years theme: Bench to Bedside to Benefit - Creating Value for Patients through CGT Translational Science, will integrate the full chorus of voices discussing four main topics: Innovation and R&D the cool new technology; translation into the clinic; late-stage clinical development; and launch and patient access.
Speaking of cool new technology, Geneva, Switzerland-based Antion will be presenting new data around its proprietary miCAR platform, which aims to overcome some of the current limitations in gene editing.
Gene editing, as incredible and as powerful as it is, has some major drawbacks when we try to make more than three or four changes to a cell. As we try to make more and more changes to cells, which we are going to need to do as we get into more complex tumors and solid tumors, gene editing really falls down, Kili said.
This is where Antion, which recently entered into a collaboration funding agreement with Allogene Therapeutics, comes in.
This miCAR platform allows us to silence up to six different genes and add a CAR or a TCR all in a single construct, in a single transduction step, he explained, adding that the technology enables Antion to create very highly modified cells that have very high efficiency and a very good recovery, all without exhausting the cells during the manufacturing process.
This week, Antion will present data that shows the functional silencing of six different genes with a CAR and the activation and activity of the chimeric antigen receptor.
Kili said to also anticipate announcements regarding technological advances in COVID-19 and Acute Respiratory Distress Syndrome (ARDS). Interest in each is understandably at a fever pitch. The second track will focus on overcoming some of the big challenges in early clinical work, such as patient enrollment and running remote clinical trials, while the third will look at the later stages of clinical development.
Its the fourth track, however, where Kili focused most of his thoughts.
This is kind of a coming of age for ISCT, he shared. ISCT, in the many years before, was focused on a lot of R&D work and clinical translation, but we've seen in the last few years more products come into the market and this is an area of creating really good launch excellence. How do you launch and provide therapies that are good value, that change patients lives, that make patients lives easier in the administration? All of these things are going to be critical to discuss.
On May 6, Kili will host a discussion entitled Are Cell & Gene Therapies a First World Only Luxury?
We sit in our first world countries, all very happy and we have access to many of these therapies. But what about patients in South America and Sub-Saharan Africa? What are we doing as an environment about making these therapies available to them? he asked. Kili has brought together panelists including the Institute for Cellular and Molecular Medicine in South Africa, Caring Cross in the United States, Universidad de los Andes in Chile and Novartis.
Looking ahead to the next five-to-10 years, I think we're going to understand the pathophysiology and we're going to understand the cause of particularly cancers like solid tumors, but also some immunology diseases. We're going to understand them on a much better molecular level, Kili predicted. At the moment, we tend to go in, take a cancer and say, these cancer cells have got a little flag that says hello, I'm a CD19, so we say, let's arm a cell and chuck it in there. But we forget that there's an entire orchestra going on in inside that space, and then we wonder why sometimes it doesn't work.
This stronger molecular science will then translate into better understanding and better refinement of the technologies, the cell-based therapies that we're using, so our ability to penetrate and survive those cells in solid tumors in that tumor microenvironment, Kili continued.
He envisions the space making more progress in solid tumors, as well as a progression away from cancer and into immunotherapies, using cell and gene-modified cell therapies for immune conditions, such as diabetes and Systemic lupus erythematosus (SLE).
In the manufacturing space, Kili said the key will be to learn how to usevectors better to create better in vivo therapies, be they gene-modified cell therapies or pure gene therapies. All of these aspects need to move forward, he said, to allow us to decrease the cost of goods for these therapies so that we can make them available to more people both in our very privileged first world, but also in low and middle-income countries.
In conclusion, Kili said, I think we're going to see a lot of very rapid changes and very rapid improvements.
ISCT kicks off Wednesday, May 4, with the excitement continuing through Saturday. BioSpace will have the highlights from both this conference andASGCT.
Excerpt from:
At ISCT This Week, Cell & Gene Therapy Grows Up - BioSpace
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced that it will present preclinical data for its TN-401 and DWORF gene therapy programs, as well as data on its capsid engineering capabilities at the upcoming American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting taking place May 1619, 2022, in Washington, D.C. and virtually.
TN-401 is Tenayas gene therapy candidate being developed for the potential treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by PKP2 gene mutations. Mutations of the PKP2 gene are the leading genetic cause of ARVC and can result in severe disease, including significant arrhythmia and sudden cardiac death in adults and children. These mutations are estimated to affect more than 70,000 patients in the U.S. alone. Data being presented at ASGCT will detail the impact of a single dose of PKP2 gene therapy on arrhythmias, disease progression and survival in a Pkp2-deficient mouse model of ARVC. Tenaya will support the establishment of a global natural history study of ARVC caused by PKP2 mutations in 2022 and expects to submit an Investigational New Drug application (IND) to the U.S. Food and Drug Administration for TN-401 in 2023.
The companys DWORF gene therapy is being developed for the potential treatment of genetic dilated cardiomyopathy (DCM). DWORF is a muscle specific micro-peptide first discovered by Tenaya co-founder Eric Olson, Ph.D. that acts on the SERCA pathway, which is widely considered to be a promising target in heart failure. Data to be shared at ASGCT will review initial tolerability and efficacy of adeno-associated viral (AAV) delivered DWORF in a DCM mouse model. Tenayas DWORF program is currently at candidate selection stage.
Tenaya believes its capsid engineering efforts will ultimately help support successful clinical development of its product candidates by enhancing the efficacy and safety of gene therapies. Data being presented for Tenayas capsid engineering efforts will showcase the work being done to enhance the specificity and expression of genes delivered to cardiomyocytes using novel capsids.
Details of the presentations are as follows:
Tuesday, May 17, 20225:30 p.m. 6 :30 p.m. ETCardiovascular and Pulmonary Diseases session
To view full event programming, please visit the ASGCT 25th Annual Meeting website.
About Tenaya Therapeutics
Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. For more information, visit http://www.tenayatherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Words such as will, potential, expects and believes, and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, among other things, Tenayas plans to present preclinical data on its TN-401 and DWORF gene therapy programs at the ASGCT 25th Annual Meeting; the therapeutic potential of TN-401 as a treatment for ARVC caused by PKP2 gene mutations; Tenayas plans to support the establishment of a global natural history study of ARVC caused by PKP2 mutations and expectations regarding the timing of the IND filing for TN-401; the therapeutic potential of Tenayas DWORF gene therapy program as a treatment for DCM; and Tenayas belief that its capsid engineering efforts will enhance the efficacy and safety of gene therapies. The forward-looking statements contained herein are based upon Tenayas current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: the availability of data at the referenced times; risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early stage company; Tenayas ability to develop, initiate or complete preclinical studies and clinical trials, and obtain approvals, for any of its product candidates; the timing, progress and results of preclinical studies for TN-401, DWORF and Tenayas other programs; Tenayas ability to raise any additional funding it will need to continue to pursue its business and product development plans; negative impacts of the COVID-19 pandemic on Tenayas manufacturing and operations, including preclinical studies and planned clinical trials; the timing, scope and likelihood of regulatory filings and approvals; the potential for any clinical trial results to differ from preclinical, interim, preliminary, topline or expected results; Tenayas manufacturing, commercialization and marketing capabilities and strategy; the loss of key scientific or management personnel; competition in the industry in which Tenaya operates; Tenayas reliance on third parties; Tenayas ability to obtain and maintain intellectual property protection for its product candidates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled Risk Factors in documents that Tenaya files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Tenaya assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations
Ongoing Clinical Development Program Represents Largest and Longest Development Program for any Gene Therapy in Hemophilia A, Demonstrates Commitment to Advancing Care for People with Hemophilia A
SAN RAFAEL, Calif., May 5, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced five platform presentations and one poster presentation on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the World Federation of Hemophilia (WFH) 2022 World Congress from May 8-11 in Montreal, Canada.
"We're pleased to provide updated data on durability of effect in patients treated over two years ago, on molecular contributors to variability, on hepatotoxicity and the role of immunosuppression, on the potential for integration-related oncogenicity, and on health-related quality of life. We continue to learn about the potential for investigational valoctocogene roxaparvovec to transform lives and the optimal way to manage patients through their journey," said Hank Fuchs, M.D., President of Worldwide Research and Development at BioMarin. "We are progressing our regulatory efforts with the intent to deliver a therapy that may represent an important and valuable treatment choice for patients with severe Hemophilia A, as no presently available treatment offers such freedom from prophylaxis and reduced bleeding frequency at the same time."
"BioMarin is generating valuable data about investigational valoctocogene roxaparvovec that potentially could enable shared decision making between physicians and patients on what is the best therapy in each personal situation," said Professor Wolfgang Miesbach, Head of the Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre at the Goethe University Hospital in Frankfurt/Main, Germany.
Presentation of data at WFH follows positive two-year results from the ongoing, global phase 3 GENEr8-1 study of valoctocogene roxaparvovec presented at a medical meeting earlier in the year, as well as publication of one-year results from the pivotal clinical trial in the New England Journal of Medicine in March 2022.
BioMarin's presentations at WFH include:
Platform Presentations
Immune suppression following gene therapy in HemophiliaProfessor Wolfgang Miesbach, Head of the Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre, Goethe University Hospital, Frankfurt/Main, GermanyMonday, May 9, 2022, 1:30 -2:30 PM ET
Exploratory analyses of healthy liver biopsies and a single case of parotid acinar cell carcinoma do not identify a role for valoctocogene roxaparvovec vector insertion in altering cell growthKevin Eggan, Group Vice President, Head of Research and Early Development / BioMarinMonday, May 9, 2022, 1:30 -2:30 PM ET
Health-related quality of life over 2 years following valoctocogene roxaparvovec adeno-associated virus gene transfer for severe hemophilia A: Results from GENEr8-1Dr. Amy Dunn, Director of Pediatric Hematology, Nationwide Children's Hospital, Columbus, OhioTuesday, May 10, 2022, 1:30-2:30 PM ET
Human liver biopsy analysis showed interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A Sylvia Fong, Head of Hematology Research, BioMarinWednesday, May 11, 2022, 1:30 -2:30 PM ET
Interim 52-week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A Brian Long, Principal Scientist, Clinical Immunology, BioMarinWednesday, May 11, 2022, 4-5 PM ET
Poster Presentation
Use of immunosuppressives in patients with hemophilia receiving gene therapy: Evidence generation using a mixed-methods approach Professor Wolfgang Miesbach, Head of the Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre, Goethe University Hospital, Frankfurt/Main, Germany
BioMarin-Sponsored Symposia
Gene Therapy Clinical Trial Patient Journey: A Look Into Shared Decision MakingMonday, May 9, 12:15 1:15 PM ET
About Hemophilia A
People living with hemophilia A lack sufficient functioning Factor VIII protein to help their blood clot and are at risk for painful and/or potentially life-threatening bleeds from even modest injuries. Additionally, people with the most severe form of hemophilia A (FVIII levels <1%) often experience painful, spontaneous bleeds into their muscles or joints. Individuals with the most severe form of hemophilia A make up approximately 50 percent of the hemophilia A population. People with hemophilia A with moderate (FVIII 1-5%) or mild (FVIII 5-40%) disease show a much-reduced propensity to bleed. The standard of care for individuals with severe hemophilia A is a prophylactic regimen of replacement Factor VIII infusions administered intravenously up to two to three times per week or 100 to 150 infusions per year. Despite these regimens, many people continue to experience breakthrough bleeds, resulting in progressive and debilitating joint damage, which can have a major impact on their quality of life.
Hemophilia A, also called Factor VIII deficiency or classic hemophilia, is an X-linked genetic disorder caused by missing or defective Factor VIII, a clotting protein. Although it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous mutation, a new mutation that was not inherited. Approximately 1 in 10,000 people have Hemophilia A.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. For additional information, please visitwww.biomarin.com.
Forward Looking Statements
This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including without limitation, statements about: the data presented at WFH, including the five platform presentations, one poster, and one BioMarin sponsored symposia, the development of BioMarin's valoctocogene roxaparvovec program generally, the impact of valoctocogene roxaparvovec gene therapy for treating patients with severe hemophilia A and the potential to transform the lives of these patients and the ongoing clinical programs generally. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: results and timing of current and planned preclinical studies and clinical trials of valoctocogene roxaparvovec, including final analysis of the above data and additional data from the continuation of these trials and the entire development program, including further assessment of safety events, any potential adverse events observed in the continuing monitoring of the patients in the clinical trials; the content and timing of decisions by the FDA, the EMA and other regulatory authorities; the content and timing of decisions by local and central ethics committees regarding the clinical trials; our ability to successfully manufacture valoctocogene roxaparvovec; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission (SEC), including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 as such factors may be updated by any subsequent reports. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.
BioMarin is a registered trademark of BioMarin Pharmaceutical Inc.
Contacts:
Investors
Media
Traci McCarty
Debra Charlesworth
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
(415) 455-7558
(415) 455-7451
SOURCE BioMarin Pharmaceutical Inc.
The rest is here:
BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia...